Bleeding disorders treatment market report forecast till 2023

1. Report Information More information from: https://www.marketresearchfuture.com/reports/6592 Bleeding Disorders Treatment Market Report-Forecast till 2023 Report / Search Code: MRFR/HC/5129-HCRR Publish Date: January, 2019 Request Sample Price 1-user PDF : $ 4450.0 Enterprise PDF : $ 6250.0 Description: Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, and Others), Drug Class (Plasma-Derived Coagulation Factor Concentrates Market and Others), Treatment (Desmopressin, Hormone Replacement Therapy), and Region-Global Forecast till 2023 Market Scenario The Global Bleeding Disorders Treatment Market is expected to register a growth of significant CAGR 10.0% during the forecast period (2018–2023). A bleeding disorder is a condition where there is a problem with the body’s clotting method. This disorder leads to heavy and protracted bleeding after an injury. The bleeding process can also start on its own. Most of the types of bleeding disorders are hereditary but some are acquired due to liver diseases, side effects of certain medications, low red blood cell count, vitamin K deficiency and others. The global bleeding disorders treatment market is expected to witness fast growth during the forecast period due to growth in the number of people suffering from liver diseases, anemia, and other blood coagulation disorders. The global bleeding disorders treatment market is seeing a rise due to growth in the number of diagnosed patients with bleeding disorders, rising research and development activities and investments by key players growth in awareness about bleeding disorders especially hemophilia and positive government initiatives in the developed countries towards establishing a wide network of diagnosis and treatment centers complementing the market growth. However, the absence of access to proper treatment due to the high cost of medication and the shortage of skilled health professionals hinders the growth of the market. Segmentation The global bleeding disorders treatment market has been segmented on the basis of type, drug class, treatment and end users. On the basis of type, the market has been classified as hemophilia A, hemophilia B, Von Willebrand Disease (vWD) and others. On the basis of drug class, the market has been classified as plasma-derived coagulation factor concentrates market, global recombinant coagulation factor concentrate market, global others bleeding disorders treatment market. On the basis of treatment, the market has been classified as desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic/clot-stabilizing drugs, fibrin sealants, drugs applied to cuts and pipeline analysis (phase I, phase II and phase III clinical trials) On the basis of end users, the market has been classified as hospitals, clinics, specialty clinics, research institutes, and others. On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada. The European bleeding disorders treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

2. The bleeding disorders treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bleeding disorders treatment market in the Middle East and Africa has been segmented into the Middle East and Africa. Regional Market Summary Global Bleeding Disorders Treatment Market Share, by Region, 2017 (%) Source: MRFR Analysis In the bleeding disorders treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into drugs. According to the Hemophilia Federation of America, around 20,000 people are affected by hemophilia and approximately 1% of the population is suffering from Von Willebrand Disease (VWD). The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to Statista, around 149,764 people were diagnosed with hemophilia A and about 10,811 people were diagnosed with other platelet disorders in the year 2016. Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure. According to the annual report survey of 2015 by the World Federation of Hemophilia, it is estimated that there were 17,346 million people suffering from hemophilia. The market in the Middle East & Africa is expected to account for the smallest share of the global bleeding disorders treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities. Key Players Some of the key players in the global bleeding disorders treatment market are Shire Plc, Bayer Pharmaceuticals, Novo Nordisk A/S, Pfizer Inc., Biogen Idec, CSL Behring, Grifols, Octapharma, Sun Pharmaceutical Industries Ltd., BDI Pharma, Ferring Pharmaceuticals, and others. Global Bleeding Disorders Treatment Market, by Type Hemophilia A Hemophilia B Von Willebrand Disease (vWD) Others Global Bleeding Disorders Treatment Market, by Drug Class

3. Plasma-derived coagulation factor concentrates market Global recombinant coagulation factor concentrate market Global others bleeding disorders treatment market Global Bleeding Disorders Treatment Market, by Treatment Medication Desmopressin (DDAVP) Hormone replacement therapy Contraceptives Anti-fibrinolytic/clot-stabilizing drugs Fibrin sealants Drugs applied to cuts Pipeline analysis (phase I, phase II and phase III clinical trials) Global Bleeding Disorders Treatment Market, by End-Users Hospitals Clinics Research Institutes Others Global Bleeding Disorders Treatment Market, by Region Americas North America US Canada South America Europe Western Europe Germany France Italy Spain UK Rest of Western Europe Eastern Europe Asia-Pacific Japan China

4. India Australia South Korea Rest of Asia-Pacific Middle East & Africa Middle East Africa Company Profiles Shire Plc Bayer Pharmaceuticals Novo Nordisk A/S Pfizer Inc. Biogen Inc. CSL Behring Grifols Octapharma Sun Pharmaceutical Industries Ltd. BDI Pharma Ferring Pharmaceuticals Others Intended Audience Manufacturers and distributors Healthcare institutions (hospitals, laboratories, medical schools, and outpatient clinics) Research institutes Contract manufacturing organizations (CMOs) Government associations Market research and consulting firms Venture capitalists and investors Contents: Contents Table of Contents: Chapter 1. Report Prologue Chapter 2. Market Introduction 2.1 Definition 2.2 Scope of the Study 2.2.1 Research Objective 2.2.2 Assumptions 2.2.3 Limitations Chapter 3. Research Methodology 3.1 Introduction 3.2 Primary Research 3.3 Secondary Research

5. 3.4 Market Size Estimation Chapter 4. Market Dynamics 4.1 Drivers 4.2 Restraints 4.3 Opportunities 4.4 Challenges 4.5 Macroeconomic Indicators 4.6 Technology Trends & Assessment Chapter 5. Market Factor Analysis 5.1 Porter’s Five Forces Analysis 5.1.1 Bargaining Power of Suppliers 5.1.2 Bargaining Power of Buyers 5.1.3 Threat of New Entrants 5.1.4 Threat of Substitutes 5.1.5 Intensity of Rivalry 5.2 Value Chain Analysis 5.3 Investment Feasibility Analysis 5.4 Pricing Analysis Chapter 6. Global Bleeding disorders Treatment Market, by Type 6.1 Introduction 6.2 Hemophilia A Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 6.3 Hemophilia B Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 6.4 Von Willebrand Disease (vWD) Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 6.5 Others Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 Chapter 7. Global Bleeding disorders Treatment Market, by Drug Class 7.1 Introduction 7.2 Plasma-Derived Coagulation Factor Concentrates Market Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 7.3 Global Recombinant Coagulation Factor Concentrate Market Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 7.4 Global Others Bleeding Disorders Treatment Market Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 Chapter 8. Global Bleeding disorders Treatment Market, by Treatment 8.1 Introduction 8.2 Desmopressin (DDAVP) Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 8.3 Hormone Replacement Therapy Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 8.4 Contraceptives Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 8.5 Anti-Fibrinolytic/Clot-Stabilizing Drugs Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 8.6 Fibrin Sealants Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 8.6 Drugs applied to cuts Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 8.6 Pipeline Analysis (Phase I, Phase II and Phase III Clinical Trials) Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 Chapter 9. Global Bleeding disorders Treatment Market, by End-Users 9.1 Introduction 9.2 Hospitals Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 9.3 Clinics Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 9.4 Research Institutes Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 9.5 Others Market Estimates & Forecast, by Region, 2018–2023 Market Estimates & Forecast, by Country, 2018–2023 Chapter 10. Global Bleeding disorders Treatment Market, by Region

6. 10.1 Introduction 10.2 Americas 10.2.1 North America 10.2.1.1 US 10.2.1.2 Canada 10.2.2 South America 10.3 Europe 10.3.1 Western Europe 10.3.1.1 Germany 10.3.1.2 France 10.3.1.3 Italy 10.3.1.4 Spain 10.3.1.5 UK 10.3.1.6 Rest of Western Europe 10.3.2 Eastern Europe 10.4 Asia-Pacific 10.4.1 Japan 10.4.2 China 10.4.3 India 10.4.4 Australia 10.4.5 South Korea 10.4.6 Rest of Asia-Pacific 10.5 Middle East & Africa 10.5.1 Middle East 10.5.2 Africa Chapter 11. Company Landscape 11.1 Introduction 11.2 Market Share Analysis 11.3 Key Development & Strategies Chapter 12. Company Profiles 12.1 Shire Plc 12.1.1 Company Overview 12.1.2 Type Overview 12.1.3 Financials Overview 12.1.4 Key Developments 12.1.5 SWOT Analysis 12.2 Bayer Pharmaceuticals 12.2.1 Company Overview 12.2.2 Type Overview 12.2.3 Financial Overview 12.2.4 Key Developments 10.2.5 SWOT Analysis 12.3 Novo Nordisk A/S 12.3.1 Company Overview 12.3.2 Type Overview 12.3.3 Financial Overview 12.3.4 Key Development 12.3.5 SWOT Analysis 12.4 Pfizer Inc. 12.4.1 Company Overview 12.4.2 Technology/Business Segment Overview 12.4.3 Financial Overview 12.4.4 Key Development 12.4.5 SWOT Analysis 12.5 Biogen Idec 12.5.1 Company Overview 12.5.2 Type Overview 12.5.3 Financial overview 12.5.4 Key Developments 12.5.5 SWOT Analysis 12.6 CSL Behring 12.6.1 Company Overview 12.6.2 Type Overview 12.6.3 Financial Overview 12.6.4 Key Developments 12.6.5 SWOT Analysis 12.7 Grifols 12.7.1 Overview 12.7.2 Type Overview 12.7.3 Financial Overview 12.7.4 Key Developments 12.7.5 SWOT Analysis 12.8 Octapharma 12.8.1 Overview 12.8.2 Type/ Technology Overview 12.8.3 Financials 12.8.4 Key Developments 12.8.5 SWOT Analysis 12.9 Sun Pharmaceutical Industries Ltd. 12.9.1 Overview 12.9.2 Type Overview

7. 12.9.3 Financials 12.9.4 Key Developments 12.9.5 SWOT Analysis 12.10 BDI Pharma 12.10.1 Overview 12.10.2 Type Overview 12.10.3 Financials 12.10.4 Key Developments 12.10.5 SWOT Analysis 12.11 Ferring Pharmaceuticals 12.11.1 Overview 12.11.2 Type Overview 12.11.3 Financials 12.11.4 Key Developments 12.11.5 SWOT Analysis 12.12 Others 12.12.1 Overview 12.12.2 Type Overview 12.12.3 Financials 12.12.4 Key Developments 12.12.5 SWOT Analysis Chapter 13. MRFR Conclusion 13.1 Key Findings 13.1.1 From CEO’s Viewpoint 13.1.2 Unmet Needs of the Market 13.2 Key Companies to Watch 13.3 Predictions for the Bleeding Disorders Treatment Industry Chapter 14. Appendix LIST OF TABLES Table 1 Global Bleeding disorders Treatment Market Synopsis, 2018–2023 Table 2 Global Bleeding disorders Treatment Market Estimates and Forecast, 2018–2023 (USD Million) Table 3 Global Bleeding disorders Treatment Market, by Region, 2018–2023 (USD Million) Table 4 Global Bleeding disorders Treatment Market, by Type, 2018–2023 (USD Million) Table 5 Global Bleeding disorders Treatment Market, by Drug Class, 2018–2023 (USD Million) Table 6 Global Bleeding disorders Treatment Market, by Treatment, 2018–2023 (USD Million) Table 7 Global Bleeding disorders Treatment Market, by End-users, 2018–2023 (USD Million) Table 8 North America: Bleeding disorders Treatment Market, by Type, 2018–2023 (USD Million) Table 9 North America: Bleeding disorders Treatment Market, by Drug Class, 2018–2023 (USD Million) Table 10 North America: Bleeding disorders Treatment Market, by Treatment, 2018–2023 (USD Million) Table 11 North America: Bleeding disorders Treatment Market, by End-users, 2018–2023 (USD Million) Table 12 US: Bleeding disorders Treatment Market, by Type, 2018–2023 (USD Million) Table 13 US: Bleeding disorders Treatment Market, by Drug Class, 2018–2023 (USD Million) Table 14 US: Bleeding disorders Treatment Market, by Treatment, 2018–2023 (USD Million) Table 15 US: Bleeding disorders Treatment Market, by End-users, 2018–2023 (USD Million) Table 16 Canada: Bleeding disorders Treatment Market, by Type, 2018–2023 (USD Million) Table 17 Canada: Bleeding disorders Treatment Market, by Drug Class, 2018–2023 (USD Million) Table 18 Canada: Bleeding disorders Treatment Market, by Treatment, 2018–2023 (USD Million) Table 19 Canada: Bleeding disorders Treatment Market, by End-users, 2018–2023 (USD Million) Table 20 South America: Bleeding disorders Treatment Market, by Type, 2018–2023 (USD Million) Table 21 South America: Bleeding disorders Treatment Market, by Drug Class, 2018–2023 (USD Million) Table 22 South America: Bleeding disorders Treatment Market, by Treatment, 2018–2023 (USD Million) Table 23 South America: Bleeding disorders Treatment Market, by End-users, 2018–2023 (USD Million) Table 24 Europe: Bleeding disorders Treatment Market, by Type, 2018–2023 (USD Million) Table 25 Europe: Bleeding disorders Treatment Market, by Drug Class, 2018–2023 (USD Million) Table 26 Europe: Bleeding disorders Treatment Market, by Treatment, 2018–2023 (USD Million) Table 27 Europe: Bleeding disorders Treatment Market, by End-users, 2018–2023 (USD Million) Table 28 Western Europe: Bleeding disorders Treatment Market, by Type, 2018–2023 (USD Million) Table 29 Western Europe: Bleeding disorders Treatment Market, by Drug Class, 2018–2023 (USD Million) Table 30 Western Europe: Bleeding disorders Treatment Market, by Treatment, 2018–2023 (USD Million) Table 31 Western Europe: Bleeding disorders Treatment Market, by End-users, 2018–2023 (USD Million) Table 32 Eastern Europe: Bleeding disorders Treatment Market, by Type, 2018–2023 (USD Million) Table 33 Eastern Europe Bleeding disorders Treatment Market, by Drug Class, 2018–2023 (USD Million) Table 34 Eastern Europe Bleeding disorders Treatment Market, by Treatment, 2018–2023 (USD Million) Table 35 Eastern Europe: Bleeding disorders Treatment Market, by End-users, 2018–2023 (USD Million) Table 36 Asia-Pacific: Bleeding disorders Treatment Market, by Type, 2018–2023 (USD Million) Table 37 Asia-Pacific: Bleeding disorders Treatment Market, by Drug Class, 2018–2023 (USD Million) Table 38 Asia-Pacific: Bleeding disorders Treatment Market, by Treatment, 2018–2023 (USD Million) Table 39 Asia-Pacific: Bleeding disorders Treatment Market, by End-users, 2018–2023 (USD Million) Table 40 Middle East & Africa: Bleeding disorders Treatment Market, by Type, 2018–2023 (USD Million) Table 41 Middle East & Africa Bleeding disorders Treatment Market, by Drug Class, 2018–2023 (USD Million) Table 42 Middle East & Africa: Bleeding disorders Treatment Market, by Treatment, 2018–2023 (USD Million) Table 43 Middle East & Africa: Bleeding disorders Treatment Market, by End-users, 2018–2023 (USD Million) LIST OF FIGURES Figure 1 Research Process Figure 2 Segmentation for Global Bleeding disorders Treatment Market Figure 3 Segmentation Market Dynamics for Global Bleeding disorders Treatment Market Figure 4 Global Bleeding disorders Treatment Market Share, by Type, 2017 Figure 5 Global Bleeding disorders Treatment Market, by End-users, 2018–2023 (USD Million) Figure 6 Global Bleeding disorders Treatment Market Share, by Region, 2017 Figure 7 North America: Bleeding disorders Treatment Market Share, by Country, 2017

8. Figure 8 Europe: Bleeding disorders Treatment Market Share, by Country, 2017 Figure 9 Asia-Pacific: Bleeding disorders Treatment Market Share, by Country, 2017 Figure 10 Middle East & Africa: Bleeding disorders Treatment Market Share, by Country, 2017 Figure 11 Global Bleeding disorders Treatment Market: Company Share Analysis, 2017 (%) Figure 12 Shire Plc.: Key Financials Figure 13 Shire Plc: Segmental Revenue Figure 14 Shire Plc: Geographical Revenue Figure 15 Bayer Pharmaceuticals: Key Financials Figure 16 Bayer Pharmaceuticals: Segmental Revenue Figure 17 Bayer Pharmaceuticals: Geographical Revenue Figure 18 Novo Nordisk A/S: Key Financials Figure 19 Novo Nordisk A/S: Segmental Revenue Figure 20 Novo Nordisk A/S: Geographical Revenue Figure 21 Pfizer Inc.: Key Financials Figure 22 Pfizer Inc.: Segmental Revenue Figure 23 Pfizer Inc.: Geographical Revenue Figure 24 Biogen Idec: Key Financials Figure 25 Biogen Idec: Segmental Revenue Figure 26 Biogen Idec: Geographical Revenue Figure 27 CSL Behring: Key Financials Figure 28 CSL Behring: Segmental Revenue Figure 29 CSL Behring: Geographical Revenue Figure 30 Grifols: Key Financials Figure 31 Grifols: Segmental Revenue Figure 32 Grifols: Geographical Revenue Figure 33 Octapharma: Key Financials Figure 34 Octapharma: Segmental Revenue Figure 35 Octapharma: Geographical Revenue Figure 36 Sun Pharmaceutical Industries Ltd.: Key Financials Figure 37 Sun Pharmaceutical Industries Ltd.: Segmental Revenue Figure 38 Sun Pharmaceutical Industries Ltd.: Geographical Revenue Figure 39 BDI Pharma: Key Financials Figure 40 BDI Pharma: Segmental Revenue Figure 41 BDI Pharma: Geographical Revenue Figure 42 Ferring Pharmaceuticals: Key Financials Figure 43 Ferring Pharmaceuticals: Segmental Revenue Figure 44 Ferring Pharmaceuticals: Geographical Revenue Figure 45 Others: Key Financials Figure 46 Others: Segmental Revenue Figure 47 Others: Geographical Revenue marketresearchfuture.com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349